Opinion|Videos|May 12, 2025
The Impact of Tumor Heterogeneity in Ovarian Cancer
Author(s)Bradley J. Monk, MD, FACS, FACOG
A panelist discusses how tumor heterogeneity (both spatial and temporal) affects molecular testing reliability in ovarian cancer, highlighting that although most biomarkers show little heterogeneity, newer approaches like liquid biopsies can provide a more comprehensive genetic profile of the entire tumor burden.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Impact of Tumor Heterogeneity on Testing Reliability
Although ovarian cancer shows relatively limited spatial and temporal heterogeneity compared to other cancers, considerations include the following:
- More recent biopsies are preferred for testing when available.
- Blood-based testing (liquid biopsies) can provide genomic information by sampling circulating tumor DNA from the entire tumor burden.
- Cell-free DNA testing is increasingly useful but cannot yet replace tissue-based testing for protein expression markers like HER2 and folate receptor alpha.
Research continues to develop more comprehensive testing through liquid biopsy approaches.
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
Medicare GLP-1 Bridge Launches, but Who Actually Qualifies?
2
FDA Advisory Committee Supports Moderna mRNA Flu Vaccine Review
3
Online GLP-1 Sellers Often Skip Clinician Oversight
4
Early Treatment Succeeds in CRC With Next-Generation KRAS Inhibitor Calderasib Plus Cetuximab Combo
5